Gemeprost Versus Dinoprostone in First Trimester Miscarriages
NCT ID: NCT05342467
Last Updated: 2025-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
101 participants
INTERVENTIONAL
2022-11-11
2024-10-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages
NCT05304273
Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage
NCT03065660
Misoprostol for Non-Viable Pregnancies
NCT00426491
Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage
NCT07109947
The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy
NCT05341817
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gemeprost
Gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours.
Gemeprost 1 Mg Vaginal Pessary
Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
Dinoprostone 3 mg
Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
Dinoprostone
Dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours.
Gemeprost 1 Mg Vaginal Pessary
Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
Dinoprostone 3 mg
Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gemeprost 1 Mg Vaginal Pessary
Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
Dinoprostone 3 mg
Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* incomplete miscarriages
* first trimester
Exclusion Criteria
* Rhesus negative
* suspected ectopic pregnancy or pregnancy of unknown location
* on anticoagulation drug
* septic miscarriages
* hemodynamically unstable
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National University of Malaysia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rahana Abd Rahman
Role: PRINCIPAL_INVESTIGATOR
National University of Malaysia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UKM Medical Center
Kuala Lumpur, W.Persekutuan, Malaysia
UKM Medical Centre
Kuala Lumpur, W.Persekutuan, Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FF-2021-504
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.